Coherus Is Confident After US Ranibizumab Filing

Targeting Around 10% Share On Adalimumab

 
• By Aidan Fry
  
Eye
Cojerus is confident of being int he vanguard of biosimilar rivals to Roche's Lucentis ophthalmic blockbuster • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products